Equities Analysts Set Expectations for BCAX FY2026 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will earn ($1.98) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $13.01 price objective on the stock. The consensus estimate for Bicara Therapeutics' current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.28).

BCAX has been the subject of a number of other reports. HC Wainwright cut their price target on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a report on Friday, May 16th. Wedbush restated an "outperform" rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Friday, May 23rd. Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a report on Thursday, March 27th. Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price target on the stock in a report on Friday, May 23rd. Finally, Wall Street Zen lowered shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $31.86.

Bicara Therapeutics Stock Up 9.6%

Bicara Therapeutics stock traded up $1.10 during mid-day trading on Tuesday, reaching $12.58. The company's stock had a trading volume of 574,767 shares, compared to its average volume of 585,091. The firm's fifty day moving average price is $12.29 and its two-hundred day moving average price is $14.04. Bicara Therapeutics has a 12-month low of $7.80 and a 12-month high of $28.09.

Hedge Funds Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System bought a new stake in shares of Bicara Therapeutics during the 4th quarter worth $25,000. Spire Wealth Management purchased a new stake in Bicara Therapeutics during the fourth quarter valued at about $31,000. BNP Paribas Financial Markets purchased a new stake in Bicara Therapeutics during the fourth quarter valued at about $32,000. Legal & General Group Plc bought a new stake in Bicara Therapeutics during the fourth quarter worth about $33,000. Finally, Summit Investment Advisors Inc. bought a new stake in Bicara Therapeutics during the fourth quarter worth about $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.